These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 36493602)
1. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204 [TBL] [Abstract][Full Text] [Related]
3. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Rebuzzi SE; Cerbone L; Signori A; Santoni M; Murianni V; De Giorgi U; Procopio G; Porta C; Milella M; Basso U; Massari F; Maruzzo M; Iacovelli R; Battelli N; Carmisciano L; Banna GL; Buti S; Fornarini G Ther Adv Med Oncol; 2022; 14():17588359221079580. PubMed ID: 35237353 [TBL] [Abstract][Full Text] [Related]
4. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Rebuzzi SE; Signori A; Banna GL; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucali PA; Masini C; Naglieri E; Procopio G; Merler S; Tomasello L; Fratino L; Baldessari C; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Stellato M; Atzori F; Pignata S; Messina C; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Pierantoni F; Casadei C; Bersanelli M; Chiellino S; Paolieri F; Perrino M; Brunelli M; Iacovelli R; Porta C; Buti S; Fornarini G Ther Adv Med Oncol; 2021; 13():17588359211019642. PubMed ID: 34046089 [TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. Rebuzzi SE; Signori A; Banna GL; Gandini A; Fornarini G; Damassi A; Maruzzo M; De Giorgi U; Basso U; Chiellino S; Galli L; Zucali PA; Fantinel E; Naglieri E; Procopio G; Milella M; Boccardo F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Santini D; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Rescigno P; Buti S J Transl Med; 2022 Sep; 20(1):435. PubMed ID: 36180954 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996 [TBL] [Abstract][Full Text] [Related]
8. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab. Beulque Y; Kinget L; Roussel E; Mobaraki S; Laenen A; Debruyne PR; Van Herck Y; Baldewijns M; Wozniak A; Garg AD; Zucman-Rossi J; Couchy G; Albersen M; De Wever L; Haaker L; Beuselinck B Acta Oncol; 2024 Aug; 63():658-668. PubMed ID: 39129249 [TBL] [Abstract][Full Text] [Related]
9. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: Murianni V; Signori A; Buti S; Rebuzzi SE; Bimbatti D; De Giorgi U; Chiellino S; Galli L; Zucali PA; Masini C; Naglieri E; Procopio G; Milella M; Fratino L; Baldessari C; Ricotta R; Mollica V; Sorarù M; Tudini M; Prati V; Malgeri A; Atzori F; Di Napoli M; Caffo O; Spada M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Lipari H; Roviello G; Catalano F; Damassi A; Cremante M; Rescigno P; Fornarini G; Banna GL Front Oncol; 2024; 14():1307635. PubMed ID: 38410103 [TBL] [Abstract][Full Text] [Related]
10. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M BJU Int; 2024 Sep; 134(3):323-336. PubMed ID: 38659099 [TBL] [Abstract][Full Text] [Related]
11. A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study. Anpalakhan S; Banna GL; Rebuzzi SE; Fornarini G; Maruzzo M; Zucali PA; Catalano F; Antonj L; Tudini M; Fratino L; Malgeri A; Rescigno P; Signori A; Acunzo A; Silini EM; Mazzaschi G; Buti S Immunotherapy; 2024; 16(14-15):963-973. PubMed ID: 39105621 [TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610 [TBL] [Abstract][Full Text] [Related]
13. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. Tomiyama N; Tasaki Y; Hamamoto S; Sugiyama Y; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Odagiri K; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Furukawa-Hibi Y; Yasui T Int J Urol; 2023 Sep; 30(9):754-761. PubMed ID: 37150513 [TBL] [Abstract][Full Text] [Related]
14. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101 [TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791 [TBL] [Abstract][Full Text] [Related]
16. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Desai K; Brown L; Wei W; Tucker M; Kao C; Kinsey E; Rini B; Beckermann K; Zhang T; Ornstein MC Target Oncol; 2021 Sep; 16(5):633-642. PubMed ID: 34379283 [TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185 [TBL] [Abstract][Full Text] [Related]
19. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study). Rebuzzi SE; Fornarini G; Signori A; Buti S; Procopio G; De Giorgi U; Pignata S; Naglieri E; Maruzzo M; Banna GL; Rescigno P; Messina C; Mattana A; Basso U; Bimbatti D BMC Cancer; 2024 Jun; 24(1):757. PubMed ID: 38914928 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]